Conclusions:IMU-201 had no observed DLT and demonstrated preliminary signs of efficacy. The study will therefore move into Phase 1b with IMU-201 being assessed in combination with atezolizumab. Clinical trial information: NCT04432207.
....nice one!
Ann: IMUGENE PUBLICATION OF CHECKVACC ABSTRACT AT ASCO 2022, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.045(12.3%) |
Mkt cap ! $70.31M | |||
| Open | High | Low | Value | Volume |
| 35.5¢ | 35.5¢ | 31.5¢ | $1.454M | 4.367M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9055 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 28000 | 2 |
View Market Depth
| Last trade - 16.10pm 22/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |